TheraRadar
Data updated: Jun 28, 2026

ADENOSCAN (adenosine) · ASTELLAS

Trial Activity: Stable 5 active trials
Cardiovascular Approved 1995-05-18
Jump to: Indications Approvals Trials Competitors Safety Patents

Development Insights

Vastra Gotaland Region conducting 2 trials (8%)
33 indications explored (Broad Platform)
→ coronary artery disease (4 trials)
→ takotsubo syndrome (2 trials)
→ supraventricular tachycardia (svt) (1 trials)
2
Indications
--
Phase 3 Trials
31
Years on Market

Details

Status
Discontinued
First Approved
1995-05-18
Routes
INTRAVENOUS
Dosage Forms
SOLUTION

Companies

ASTELLAS
Active Ingredient: ADENOSINE

ADENOSCAN Approval History

1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
30 FDA actions from 1995 to 2014 · 1 indication expansions
Aug 2014 SUPPL
Label · Labeling
FDA Letter Label
Jan 2014 SUPPL
Label · Labeling
FDA Letter Label
Dec 2013 SUPPL
Mfg · Manufacturing (CMC)

What ADENOSCAN Treats

2 FDA approvals

Originally approved for its first indication in 1995 . Covers 2 distinct patient populations.

  • Other (2)
📋

Clinical Trial Registry

25 trials
Trial Sponsor ID Phase Status Title
NCT06993038 COMFORT-ED 202412202 Ph 4 recruiting Adenosine vs Diltiazem for Treatment of SVT in the ED
NCT03218137 1609017561 Ph 4 recruiting Use of Adenosine to Determine the Electrophysiological Mechanism of Premature Ventricular Contractions
NCT06578234 HYPER 2023-505248-20-00 Ph 4 recruiting Hyperemic mYocardial Perfusion by adEnosine at diffeRent Doses
NCT06717685 PIC001/2024 Ph 3 recruiting Efficacy of Adenosine as Compared to Verapamil in Paroxysmal Supraventricular Tachycardia (pSVT) Patients
NCT04666454 BROKEN SWEDEHEART Ph 4 recruiting BROKEN-SWEDEHEART- Optimized Pharmacological Treatment for Broken Heart (Takotsubo) Syndrome.
NCT03557385 ACCELERATION results posted Pro00093001 Ph 4 completed Adenosine Contrast CorrELations in Evaluating RevAscularizaTION
NCT05014061 A-STAMI EudraCT number: 2021-001466-37 Ph 3 withdrawn Adenosine's Effect on STunning Resolution in Acute Myocardial Infarction
NCT04588441 IRB202002127 OCR39505 Ph 2 withdrawn The ARCTIC Trial: Aerosolized Inhaled Adenosine Treatment in Patients With Acute Respiratory Distress Syndrome (ARDS) Caused by COVID-19
NCT03236311 results posted ACT14656 2016-000629-38, U1111-1182-1709 Ph 2 terminated A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI
NCT04392362 AHAvsSIM results posted UPretoria Ph 3 completed A Trial to Compare American Heart Association (AHA) and Simple (SIM)Method to Give Adenosine to Treat Supra-ventricular Tachycardia (SVT)
NCT04699110 ERC-76/2020 Ph 4 completed Adrenaline for the Treatment of No-Reflow in Normotensive Patients
NCT03249272 results posted Pro00082447 Ph 4 terminated Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve
NCT02867878 TITAN 160596 Ph 2 terminated Adenosin to Rapidly Reverse Left Ventricle Impairment in Takotsubo Syndrome
NCT01690884 120477 Ph 1 completed Effect of Ticagrelor vs. Dipyridamole on Adenosine Uptake
NCT02462941 AAAO8054 Ph 1 completed Analysis of Adenosine on Sinus and Atrioventricular Nodal Conduction in the Pediatric Transplanted Heart
NCT03032965 results posted HUM00048922 Ph 2 completed Adenosine to Assess Complete Conduction Block During Catheter Ablation of Paroxysmal Atrial Fibrillation
NCT03231371 CFR-OHT results posted HUM23585 Ph 3 completed Coronary Artery Vasculopathy in Pediatric Heart Transplant Patients
NCT01161121 results posted Rega-9I06 Ph 1 completed Comparison of Intravenous Adenosine Infusion With Regadenoson Bolus for Inducing Maximal Coronary Hyperemia
NCT01234870 results posted CR1_STU00006013 ASCA-9J02 Ph 2, Ph 3 completed Comprehensive Evaluation of Ischemic Heart Disease Using MRI
NCT01809743 NL42049.060.12 Ph 3 completed Regadenoson and Adenosine
NCT00781404 PROMISE HUValldHebronRI 2007-006671-36 Ph 3 completed Myocardial Protection With Adenosine During Primary Percutaneous Coronary Intervention in Pts With STEMI
NCT00590070 REOPEN-AMI REOPEN-AMI 2007-006794-93 2007-006794-93 Ph 2, Ph 3 completed THE REOPEN-AMI STUDY - Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction
NCT01148147 PREVENT-ICARUS CE 93/09 2009-013681-92 Ph 3 completed Intracoronary Adenosine Administration to Prevent Periprocedural Myonecrosis in Elective Coronary Angioplasty
NCT01123525 AdCard 2010 2008-004274-40 Ph 1, Ph 2 completed Adenosine Cardioplegia; Improved Cardioprotection?
NCT00881686 xinzangwaike0002 Ph 1, Ph 2 completed Myocardial Protection With Adenosine Preconditioning
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ADENOSCAN FDA Label Details

Track ADENOSCAN with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

FDA Approval: NDA020059 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.

How We Calculate These Metrics

Trial Activity Stage

Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.

Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.

  • Growth: High proportion of early-phase trials (Phase 1/2), active development
  • Expansion: Significant Phase 3 activity, approaching or pursuing approvals
  • Mature: Substantial Phase 4 post-marketing studies
  • Stable: Mixed phase distribution, steady development
  • Declining: Low active trial ratio, reduced R&D investment